The authors revise the concept of ALK-negative anaplastic large cell lymphoma (ALCL) in the light of the recently updated WHO classification of Tumors of Hematopoietic and Lymphoid Tissues both on biological and clinical grounds. The main histological findings are illustrated as well as the phenotypic, molecular and clinical characteristics. Finally, the biological rationale for possible innovative targeted therapies is presented.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206530 | PMC |
| http://dx.doi.org/10.4081/pr.2011.s2.e5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nursing practices for a patient with ALK-negative anaplastic large cell lymphoma with a cancerous wound: a case report.
Wound Manag Prev
December 2024
Background: Cancerous wounds are a significant challenge in cancer care, reducing the quality of life and affecting psychological well-being.
Purpose: This case report describes a 59-year-old female who developed a severe cancerous wound. The report presents comprehensive nursing measures for patients with cancerous wounds and discusses key nursing factors that promote wound healing.
A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell Lymphomas.
Clin Lymphoma Myeloma Leuk
December 2024
Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO. Electronic address:
Introduction: Histone deacetylase inhibitors (HDACi) and combination chemotherapy are independently used to treat relapsed/refractory (R/R) lymphoma. In vitro studies suggest that the addition of HDACi to platinum-based chemotherapy is synergistic.
Patients And Methods: We conducted a phase I study of romidepsin, gemcitabine, oxaliplatin and dexamethasone (Romi-GemOxD) in R/R aggressive lymphomas with an expansion cohort in T-cell lymphomas.
Primary Cutaneous Anaplastic Large Cell Lymphoma With Rare Extracutaneous Disseminated Disease: A Case Report.
Am J Dermatopathol
December 2024
Department of Dermatology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA; and.
Primary cutaneous anaplastic large cell lymphoma (pcALCL) is a CD30+ lymphoproliferative disorder with generally favorable outcomes and infrequent extracutaneous spread, usually limited to local lymph nodes. However, there may be extensive histologic overlap with more aggressive CD30+ lymphomas, such as large cell transformation of mycosis fungoides or secondary skin involvement by anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma. Definitive diagnosis relies on clinicopathologic correlation.
View Article and Find Full Text PDFThe role of stem cell transplant (auto and allo) in PTCL and CTCL.
Hematology Am Soc Hematol Educ Program
December 2024
Department of Medicine A, University Hospital Muenster, Muenster, Germany.
In contrast to B-cell lymphoma, the advent of modern targeting drugs and immunotherapeutics has not led to major breakthroughs in the treatment of peripheral T-cell lymphoma (PTCL) to date. Therefore, both autologous and allogeneic hematopoietic cell transplantation (HCT) continue to play a central role in the management of PTCL. Focusing on the most common entities (PTCL not otherwise specified, angioimmunoblastic T-cell lymphoma, and ALK-negative anaplastic large cell lymphoma), we summarize evidence, indications, and points to consider for transplant strategies in PTCL by treatment line.
View Article and Find Full Text PDFIncidental discovery of invasive lobular carcinoma and anaplastic large cell lymphoma during sentinel lymph node biopsy: a case report.
Front Oncol
November 2024
Department of Surgery, Dankook University College of Medicine, Cheonan, Republic of Korea.
This study reports a rare case of concurrent invasive lobular carcinoma (ILC) of the breast and ALK-negative anaplastic large cell lymphoma (ALCL) detected during sentinel lymph node biopsy (SLNB). A 55-year-old female underwent breast cancer surgery following abnormal breast screening results, revealing ILC histologically. Unexpectedly, SLNB identified ALCL, later confirmed on pathology.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!